Amgen, a biotechnology leader since 1980, operates its pivotal Europe, Latin America, Middle East, Africa, and Canada (ELMAC) Hub from Rotkreuz in the Greater Zurich Area. This strategic hub, as well as Amgen Switzerland, plays a crucial role in the company's ongoing efforts to develop treatments for serious illnesses and extend its influence across these diverse regions.
A biotechnology pioneer since 1980, Amgen is one of the world’s leading biotechnology companies. Amgen’s values are deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses. With its worldwide headquarters in California, Amgen is now active in more than 100 countries. Amgen’s top priority is to help patients. Using science, research and strong innovation, new therapies are being developed continually for diseases that have been difficult or impossible to treat up until now.
Originally establishing its international corporate office in Switzerland back in 1989, Amgen Europe moved to its current location in Rotkreuz in 2018, from where it oversees all of the European markets. The office has grown to over 180 employees. Rotkreuz is also home to Amgen’s Swiss affiliate. With a beautiful setting, economic and political stability, and exceptional infrastructure, it is a highly attractive business location offering ideal growth opportunities for Amgen.
The Greater Zurich region possesses an extremely well-trained workforce from both Switzerland and abroad. The proximity to Zurich Airport is another strong point in its favor for the globally-active company. Furthermore, Switzerland is a key location for Amgen's clinical research, and it collaborates with numerous Swiss hospitals. Amgen also attaches great importance to fostering the next generation in Switzerland and supports tomorrow's scientists with projects such as educational support in primary schools and the renowned Amgen Scholars' Program at ETH Zurich.